{"entity":{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","aka":[],"tldr":"Stanford spin-out whose PhasED-Seq ctDNA technology detects residual lymphoma more accurately than PET/CT; clinical launch of CLARITY in 2026.","summary":"Foresight CLARITY uses phased variants on single cfDNA fragments to reach parts-per-million sensitivity. A pooled JCO analysis showed end-of-therapy MRD outperforms PET/CT in large B-cell lymphoma; SHORTEN-ctDNA (Columbia) tests MRD-guided chemotherapy de-escalation; a Hodgkin lymphoma MRD-guided trial launched 2026.","asOf":"2026-09-04","links":[{"label":"CLARITY platform","url":"https://foresight-dx.com/foresight-products-services/foresight-clarity/"}],"tags":[],"related":[],"cancers":["dlbcl","hodgkin-lymphoma"],"sections":["diagnostics"],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":["nct06500273"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boulder, CO","country":"US","companyType":"diagnostics","website":"https://foresight-dx.com","investors":[],"funding":[]},"route":"/companies/foresight-diagnostics/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/"},{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"trial":[{"id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"}],"idea":[{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/"},{"id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/"}]}}